Ontada

Recently, the McKesson Compile and Ontada marketing teams came together for an offsite centered on reflection, alignment and shaping a shared vision for the year ahead. The energy and openness in the room reinforced our collective focus and what matters most. Looking forward to another year of continued collaboration and shared impact. #RWD #CommunityOncology #TeamMcKesson #Marketing

In the aftermath of significant policy changes in 2025, the landscape of health economic and outcomes research (HEOR), real-world evidence (RWE), and market access (MA) is shifting dramatically. Now more than ever, adaptability is key. In this article from HealthEconomics.com | A Scientist.com Company, Ontada's Jess Paulus and Zhaohui Su provide insights into how the practical application of real-world data in the current environment can impact decision-making and accessibility. Read the full article here: https://lnkd.in/gw-kjgpe

In this interview with AJMC - The American Journal of Managed Care, Ontada's Senior Medical Director Ira Zackon, MD, discusses the role of BTK inhibitors in the treatment of chronic lymphocytic leukemia. Recent studies of real-world data indicate high discontinuation rates for covalent BTK inhibitors in CLL, suggesting time-limited therapy advantages. Read the full interview here: https://lnkd.in/gA4fmepE #BTKInhibitors #RWD #CommunityOncology #CLL #ASH25

March is Multiple Myeloma Awareness Month. Ontada is proud to contribute to the research being done into this disease. While multiple myeloma is still considered incurable, ongoing studies are providing better treatment options. In fact, according to Dr. Mohit Narang, "the five-year relative survival rate has nearly doubled in the last 30 years." In our upcoming OncoTalks Micro-Series, Dr. Narang discusses what the future of research and treatment could look like and more. Watch the series trailer below—and keep your eyes peeled on LinkedIn for the first episode release on April 8. #MultipleMyelomaAwarenessMonth #BloodCancer #Leukemia #RWD

Curbside Connect is a valuable tool that offers providers education and support when and where they need it. The 15- to 20-minute expert consultations give physicians a chance to stay current, collaborate meaningfully, and deliver high-quality care. In this Ontada Learn interview hosted by Tulsi Patel, clinical director at Ontada, Douglas Reznick, MD and Dr. Hyun Sue Kim, oncologists at Rocky Mountain Cancer Centers, discuss the positive impact of the Curbside Connect program and how it leads to better patient outcomes. #OntadaLearn #CurbsideConnect #Collaboration

What happens after a prescription is written is not always visible. Beginning in April, Ontada’s oncology dispensing dataset expands to include data from Florida Cancer Specialists & Research Institute. This added visibility helps teams assess real‑world treatment activity in community oncology, beyond prescription intent alone. Learn what’s included: https://lnkd.in/g3ku7g7m #CommunityOncology #LifeSciences #CancerResearch #RWR

WATCH/READ: Ontada's Ira Zackon, MD, discusses how sustained median hemoglobin levels can dictate overall survival outcomes for patients managing myelodysplastic syndrome (MDS). This research was presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Learn more here: https://lnkd.in/gEcknc_x #MDS #Anemia #RWD #ASH25

Access and continuity shape how community oncology data can be used. Beginning in April, Ontada will serve as the commercialization partner for Florida Cancer Specialists & Research Institute data. For life sciences teams, this means access to community oncology data representing nearly 1 in 4 cancer patients in the U.S., supporting real‑world research and more informed brand strategy decisions over time. Learn what this partnership enables: https://lnkd.in/g3ku7g7m #CommunityOncology #LifeSciences #CancerResearch #RWR

LISTEN: Ontada's Molly Brady recently joined leaders from CoverMyMeds to talk about the launch of their new Specialty Access and Affordability Solutions, an industry‑first approach embedding specialty medication access workflows directly into Ontada’s iKnowMed EHR. They discussed how automation and AI‑driven insights can accelerate therapy starts, improve predictability, and better support oncology practices and patient outcomes. Tune in at the link below. #SpecialtyCare #EHR #AI #CommunityOncology #HIMSS26